share_log

Pfizer | 4: Statement of changes in beneficial ownership of securities-Director NARAYEN SHANTANU

Pfizer | 4: Statement of changes in beneficial ownership of securities-Director NARAYEN SHANTANU

輝瑞 | 4：持股變動聲明-董事 NARAYEN SHANTANU
美股sec公告 ·  04/27 01:28
牛牛AI助理已提取核心訊息
Shantanu Narayen, a reporting person for Pfizer Inc [PFE], was involved in a transaction on April 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of shares, transaction price, and post-transaction shareholding, were not disclosed in the announcement. As such, the impact of this event on Narayen's holdings and the overall market position of Pfizer remains unclear.
Shantanu Narayen, a reporting person for Pfizer Inc [PFE], was involved in a transaction on April 25, 2024. The specific details of the transaction, including the action type, status, number of shares involved, nature of shares, transaction price, and post-transaction shareholding, were not disclosed in the announcement. As such, the impact of this event on Narayen's holdings and the overall market position of Pfizer remains unclear.
輝瑞公司 [PFE] 的舉報人尚塔努·納拉延於2024年4月25日參與了一筆交易。公告中未披露交易的具體細節，包括行動類型、狀態、所涉股份數量、股票性質、交易價格和交易後的持股情況。因此，該事件對納拉延持股和輝瑞整體市場地位的影響尚不清楚。
輝瑞公司 [PFE] 的舉報人尚塔努·納拉延於2024年4月25日參與了一筆交易。公告中未披露交易的具體細節，包括行動類型、狀態、所涉股份數量、股票性質、交易價格和交易後的持股情況。因此，該事件對納拉延持股和輝瑞整體市場地位的影響尚不清楚。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。